by Dina Aristiya Sumarno

Submission date: 15-Aug-2022 03:55PM (UTC+0800)

Submission ID: 1882700242

File name: artikel-Effectiveness of isoniazid.pdf (253.14K)

Word count: 3594

Character count: 18477

Dina Aristiya Sumarno¹, *Retno Asih Setyoningrum¹, Hari Basuki Notobroto²

Sri Lanka Journal of Child Health, 2022; 51(2): 209-214 DOI: http://dx.doi.org/10.4038/sljch.v51i2.10119

Abstract

Introduction: Childhood tuberculosis (TB) is yet a major problem in developing countries. Isoniazid preventive therapy (IPT) is recommended for children below 5 years of age who are household contacts of smear positive adult TB patients.

Objectives: To assess effectiveness of the six month IPT therapy and the risk factors for IPT failure in children less than 5 years old who are household contacts of smear positive adult TB patients.

Method: A prospective longitudinal cohort study was carried out in the Surabaya Public Health Centre from January to June 2019 in children below 5 years of age who were household contacts of smear positive adult TB patients and who were given isoniazid for 6 months. Bivariate analysis using Chi-Square test and multivariate analysis were used. p <0.05 was considered significant.

Results: Ninety one children below 5 years of age met the inclusion criteria and were included in study. Efficacy of IPT was 95.5%. In multivariate analysis, the risk factors associated with IPT failure were child contacts living in house without ventilation (p = 0.007) and incomplete IPT (p = 0.007).

Conclusions: Efficacy of IPT in reducing the incidence of TB in children below 5 years of age who were household contacts of smear positive adult TB patients was 95.5%. Low adherence to completion of therapy and unavailability of house ventilation were associated with IPT failure.

Department of Child Health, Faculty of Medicine, Universitas Airlangga, Indonesia, Department of Biostatistics and Population, Faculty of Public Health, Universitas Airlangga, Indonesia

*Correspondence: retnosoedijo@yahoo.co.id

https://orcid.org/0000-0002-2273-4924 (Received on 14 September 2021: Accepted after revision on 22 October 2021)

The authors declare that there are no conflicts of interest

Personal funding was used for the project.

Open Access Article published under the Creative

Commons Attribution CC-BY © ① License

(Key words: Toddlers, Contacts, TB, IPT, Effectiveness)

Introduction

Tuberculosis (TB) in children accounts for 11% of TB globally¹ and most get infected through close household contact with an adult TB patient². 'End TB' strategy targets in Indonesia are increasing case finding and providing isoniazid preventive therapy (IPT) to children in close contact with adult TB patients³. Operational matters are reported to be the main factor of IPT programme outcome⁴. There is a lack of studies about effectiveness of IPT and factors which contribute to IPT failure in Indonesia.

Objectives

To assess the effectiveness of the six month IPT therapy and the risk factors for IPT failure in children less than 5 years old who are household contacts of smear positive adult TB patients.

Method

A prospective longitudinal cohort study was conducted in the Surabaya Public Health Centre from January to June 2019.

Inclusion criteria: 1) Children under 5 years old, 2) in close contact or living at home with positive smear adult TB patients, diagnosed at least 1 month ago, 3) who had no symptom or sign of TB disease⁵, 4) parents signed the informed consent.

Exclusion criteria: children who already received treatment for TB.

For each subject isoniazid (INH) 10 mg/kg/day was given once daily for 6 months. Regular follow up was conducted monthly to evaluate symptoms/signs of TB disease and INH side effects. Subjects who could not be followed up due to any reason were dropped from the study. Nutritional status was evaluated based on Indonesia Paediatric Nutrition Care nutritional status⁶.

At the end of the study, effectiveness was calculated based on the number of subjects who did not develop TB disease. It was considered as IPT failure if the subjects developed TB disease, and/ or was lost to follow up (subjects who did not take IPT for 1 month in a row or more) or died during observation period.

Ethical issues: Study was approved by the Ethical Committee of Faculty of Medicine Universitas Airlangga Surabaya, Indonesia (No 319/EC/KEPK/

FKUA/2018). Written informed consent was obtained from the parents of the children participating in the study.

Statistical analysis: Data collected were analysed using Chi-square. Relative Risk was calculated on risk factors with a p value <0.05. Risk factors with a

p value <0.25 were further analysed using logistic regression. All analyses were done using SPSS 21.

Results

There were 91 subjects included in study. Figure 1 shows sample recruitment. Table 1 describes characteristics of subjects.




Figure 1: Sample recruitment

Table 1: Characteristics of Subjects (n=91)

Characteristic	Categories	Number (%)
Sex	Male	40 (44.6)
	Female	51 (55.4)
Age (years)	<1	20 (22.0)
3.0	1-2	29 (31.9)
	>2 - <5	42 (46.2)
Nutritional status	Normal	85 (93.4)
	Malnutrition	06 (06.6)
BCG scar	Yes	85 (93.4)
	No	06 (06.6)
Tuberculin test	Positive	07 (07.7)
	Negative	25 (27.5)
	Unavailable	59 (64.8)
IHC visits	Routinely every month	54 (59.3)
	Not routinely every month	37 (40.7)
House ventilation	No ventilation	09 (09.9)
	≥ 1 ventilation	82 (90.1)
Distance to IHC	≤ 1 km	55 (60.4)
	> 1 km	36 (39.6)
Adult TB source		
Relationship with subject	Parent	57 (62.6)
	Grandmother/grandfather	28 (30.8)
	Sibling	02 (02.2)
	Other	04 (04.4)
Anti-TB drug treatment	In treatment	91 (100.0)
Location	In the same house	59 (64.8)
	Close contact but different house	32 (35.2)
Isoniazid preventive therapy (IPT)		
Adherence to IPT completion	Incomplete	09 (09.9)
	Complete	82 (90.1)
Result of IPT	Successful (did not develop TB)	85 (93.4)
	Unsuccessful (developed TB)	04 (04.4)
	Loss to follow up	02 (02.2)
The reason for stopping IPT	Did not stop IPT	89 (97.8)
	Parents refused to continue IPT	02 (02.2)
Symptoms and signs of TB in child		
Symptoms of TB	Cough > 2 weeks	02 (02.2)
	Fever > 2 weeks	02 (02.2)
Signs of TB	Body temperature > 38°C	02 (02.2)
	Respiratory signs	02 (02.2)

1

At the end of the six month study period, there were 4 subjects who developed TB. Therefore, the effectiveness of IPT to prevent TB disease was 95.5%.

Table 2 shows the bivariate analysis of risk factors of IPT failure. There were 8 risk factors associated

significantly with IPT failure (p <0.05). These were age, nutritional status, BCG scar, tuberculin test, Integrated Healthcare Centre (IHC) visits, availability of house ventilation, the distance to IHC and adherence to IPT completion (Table 2).

Table 2: Bivariate analysis of risk factors of isoniazid preventive therapy (IPT) failure

Name		Result of IPT				
Sex Male 36 (90.0)	Variable	Successful	Failed	Total	p p	RR
Male 36 (90.0) 04 (10.0) 40 (100.0) 0.399 Female 49 (96.1) 02 (03.9) 51 (100.0) 0.399 Age (years) 20 (100.0) 0 (0) 20 (100.0) 0.023* <1 20 (100.0) 0 (0) 20 (100.0) 0.023* 1-2 24 (82.8) 05 (17.2) 29 (100.0) 0.023* Nuritional status 82 (96.5) 03 (03.5) 85 (100.0) 0.003* 1. Nalmatrition 03 (50.0) 03 (50.0) 06 (100.0) 0.003* 1. BCG scar Yes 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7. Yes 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7. Tuberculin test Positive 04 (57.1) 03 (42.9) 07 (100.0) 0.003* Negative 25 (100.0) 0 (0) 25 (100.0) 0.003* 0.003* Unavailable 56 (94.9) 03 (05.1) 59 (100.0) 0.003* Not routinely every month 54 (100.0)		n (%)	n (%)	n (%)	_	
Female	Sex	(12)		())		
Age (years) 20 (100.0) 0 (0) 20 (100.0) 1-2 24 (82.8) 05 (17.2) 29 (100.0) 0.023* 2-2 < 5 41 (97.6) 01 (2.4) 42 (100.0) 0.003* 1 1 1 1 1 1 1 1 1	Male	36 (90.0)	04 (10.0)	40 (100.0)	0.399	-
Age (years) 20 (100.0) 0 (0) 20 (100.0) 1-2 24 (82.8) 05 (17.2) 29 (100.0) 0.023* 2-2 < 5 41 (97.6) 01 (2.4) 42 (100.0) 0.023* 2-2 < 5 41 (97.6) 01 (2.4) 42 (100.0) 0.003* 1 0.003* 0.003* 1 0.003* 0.003* 1 0.003* 0.003* 0.003* 1 0.003*	Female	49 (96.1)	02 (03.9)	51 (100.0)		
Company	Age (years)					
1-2		20 (100.0)	0(0)	20 (100.0)		
> 2 - < 5	1-2		05 (17.2)	29 (100.0)	0.023*	
Nutritional status S2 (96.5) O3 (03.5) S5 (100.0) O.003* D.003* D.003*	> 2 - < 5					
Malnutrition 03 (50.0) 03 (50.0) 06 (100.0) BCG scar 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7 No 04 (66.7) 02 (33.3) 06 (100.0) 7 7 Tuberculin test Positive 04 (57.1) 03 (42.9) 07 (100.0) 0.003* 7 Negative 25 (100.0) 0 (0) 25 (100.0) 0 (0) 25 (100.0) 0.003* 1 IHC visits Routinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* House ventilation availability None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.003* ≥ 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* ≥ 1 km 30 (83.3) 07 (100.0) 0.003*	Nutritional status	()		, , , , , , , , , , , , , , , , , , , ,		
Malnutrition 03 (50.0) 03 (50.0) 06 (100.0) BCG scar 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7 No 04 (66.7) 02 (33.3) 06 (100.0) 7 7 Tuberculin test Positive 04 (57.1) 03 (42.9) 07 (100.0) 0.003* 7 Negative 25 (100.0) 0 (0) 25 (100.0) 0 (0) 25 (100.0) 0.003* 1 IHC visits Routinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* House ventilation availability None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.003* ≥ 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* ≥ 1 km 30 (83.3) 07 (100.0) 0.003*	Normal	82 (96.5)	03 (03.5)	85 (100.0)	0.003*	14.2
BCG scar 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7 Yes 81 (95.3) 04 (04.7) 85 (100.0) 0.049* 7 No 04 (66.7) 02 (33.3) 06 (100.0) 0 100.00 Positive 04 (57.1) 03 (42.9) 07 (100.0) 0.003* Negative 25 (100.0) 0 (0) 25 (100.0) 0.003* Unavailable 56 (94.9) 03 (05.1) 59 (100.0) 0.003* HHC visits Routinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* House ventilation availability None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.003* ≥ 1 km 55 (100.0) 55 (100.0) 55 (100.0) 0.003* ≥ 1 km	Malnutrition					
Yes 81 (95.3) 04 (04.7) 02 (33.3) 85 (100.0) 0.049* 7 No 04 (66.7) 02 (33.3) 06 (100.0) 7 Tuberculin test 04 (57.1) 03 (42.9) 07 (100.0) 0 0 Negative 25 (100.0) 0 (0) 25 (100.0) 0.003* 0.003* 0 Unavailable 56 (94.9) 03 (05.1) 59 (100.0) 0.003* HHC visits Routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* Not routinely every month More ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 0.001* None 05 (55.6) 02 (20.4) 82 (100.0) 0.001* 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.003* 0.003* > 1 km 55 (100.0) 0 (0) 55 (100.0) 0.003* 0.003* > 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* 0.003* Adult TB source 8elationship with subject 8elationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) 0.000 0.600 Sibling 02 (100.0) 0 (0) 0 (2 (100.0) 0.000 0.600 Sibling 02 (100.0) 0 (0) 0			1 (2.2.2)			1
No 04 (66.7) 02 (33.3) 06 (100.0) Tuberculin test 04 (57.1) 03 (42.9) 07 (100.0) Negative 25 (100.0) 0 (0) 25 (100.0) 0.003* Unavailable 56 (94.9) 03 (05.1) 59 (100.0) 0.003* Housinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* House ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.001* 1 ≥ 1 km 55 (100.0) 0 (0) 55 (100.0) 0.003* 0.003* ≥ 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source 2 Relationship with subject 8 Parent 54 (94.7) 03 (05.3) 57 (100.0) 0.600 S		81 (95.3)	04 (04.7)	85 (100.0)	0.049*	7.5
Tuberculin test 04 (57.1) 03 (42.9) 07 (100.0) Negative 25 (100.0) 0 (0) 25 (100.0) 0.003* Unavailable 56 (94.9) 03 (05.1) 59 (100.0) 0.003* IHC visits Routinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.003* House ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 No routinely every month 80 (97.6) 02 (02.4) 82 (100.0) 0.001* 1 None 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 2 I km 55 (100.0) 0 (0) 55 (100.0) 0.003* 0 > 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source Relationship with subject 75 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibl	No					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		()		(20010)		
Negative Unavailable 25 (100.0) 0 (0) 25 (100.0) 0.003* HC visits Secure of the control of the contro		04 (57.1)	03 (42.9)	07 (100.0)		
Unavailable 56 (94.9) 03 (05.1) 59 (100.0) IHC visits Soutinely every month 54 (100.0) 0 (0) 54 (100.0) 0.003* Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) 0.001* House ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 None 80 (97.6) 02 (02.4) 82 (100.0) 0.001* 1 Distance to IHC 55 (100.0) 0 (0) 55 (100.0) 0.003* > 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) 0.600 Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0 Other 04 (100.0) 0 (0) 02 (100.0) 0 In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house					0.003*	
IHC visits Routinely every month $54 (100.0) $						
Routinely every month $54 (100.0)$ $0 (0)$ $54 (100.0)$ 0.003^* Not routinely every month $31 (83.8)$ $06 (16.2)$ $37 (100.0)$ House ventilation availability None $05 (55.6)$ $04 (44.4)$ $09 (100.0)$ 0.001^* None $05 (55.6)$ $04 (44.4)$ $09 (100.0)$ 0.001^* 1 ≥ 1 ventilation $80 (97.6)$ $02 (02.4)$ $82 (100.0)$ 0.001^* 1 ≥ 1 km $55 (100.0)$ $0 (0)$ $55 (100.0)$ 0.003^* <	IHC visits					
Not routinely every month 31 (83.8) 06 (16.2) 37 (100.0) House ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* None 05 (55.6) 02 (02.4) 82 (100.0) 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.001* ≥ 1 km 55 (100.0) 0 (0) 55 (100.0) 0.003* > 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) 0.600 Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0.600 Other 04 (100.0) 0 (0) 04 (100.0) 0.00 Location 1 1.000 0.00 0.00 In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (1		54 (100.0)	0 (0)	54 (100.0)	0.003*	
House ventilation availability 05 (55.6) 04 (44.4) 09 (100.0) 0.001* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.001* 1 Distance to IHC 55 (100.0) 0 (0) 55 (100.0) 0.003* ≥ 1 km 55 (100.0) 0 (616.7) 36 (100.0) Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0 Other 04 (100.0) 0 (0) 04 (100.0) 0 Location 1 1.000 1.000 1.000 Close contact but different house 55 (93.2) 04 (06.8) 59 (100.0) 1.000						
None 05 (55.6) 04 (44.4) 09 (100.0) 0.001^* 1 ≥ 1 ventilation 80 (97.6) 02 (02.4) 82 (100.0) 0.001* 1 Distance to IHC 30 (80.0) 0 (0) 55 (100.0) 0.003* 0.003* ≥ 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) 67 (100.0) 0.600 67 (100.0) 0.600 <t< td=""><td></td><td></td><td></td><td> ()</td><td></td><td></td></t<>				()		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		05 (55.6)	04 (44.4)	09 (100.0)	0.001*	18.2
Distance to IHC ≤ 1 km 55 (100.0) 0 (0) 55 (100.0) 0.003* ≤ 1 km 30 (83.3) 06 (16.7) 36 (100.0) 0.003* Adult TB source 8 8 8 100.00 0.00 0.003* 0.00	> 1 ventilation					
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		00 (0.110)		02 (10010)		
> 1 km 30 (83.3) 06 (16.7) 36 (100.0) Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) Other 04 (100.0) 0 (0) 04 (100.0) Location In the same house 55 (93.2) 04 (06.8) 59 (100.0) Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0)		55 (100.0)	0 (0)	55 (100.0)	0.003*	
Adult TB source Relationship with subject Parent 54 (94.7) 03 (05.3) 57 (100.0) Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0 Other 04 (100.0) 0 (0) 04 (100.0) 0 Location 1n the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0) 1.000						
Relationship with subject 54 (94.7) 03 (05.3) 57 (100.0) Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0 Other 04 (100.0) 0 (0) 04 (100.0) 0 Location 1n the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0) 1.000	Adult TB source	(00.0)				
Parent 54 (94.7) 03 (05.3) 57 (100.0) Grandmother/grandfather 25 (89.3) 03 (10.7) 28 (100.0) 0.600 Sibling 02 (100.0) 0 (0) 02 (100.0) 0 Other 04 (100.0) 0 (0) 04 (100.0) 0 Location In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0) 32 (100.0)						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		54 (94.7)	03 (05.3)	57 (100.0)		
Sibling 02 (100.0) 0 (0) 02 (100.0) Other 04 (100.0) 0 (0) 04 (100.0) Location In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0) 1.000					0.600	
Other 04 (100.0) 0 (0) 04 (100.0) Location In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0)					0.000	
Location 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0)						
In the same house 55 (93.2) 04 (06.8) 59 (100.0) 1.000 Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0)		0.(.00.0)	1 0 (0)	0.(100.0)		
Close contact but different house 30 (93.8) 02 (06.3) 32 (100.0)		55 (93.2)	04 (06.8)	59 (100.0)	1.000	
		80 (97.6)	02 (02.4)	82 (100.0)	0.001*	18.2
Incomplete 05 (55.6) 04 (44.4) 09 (100.0)						10.2

^{*}significant

Table 3 shows the multivariate analysis of risk factors of IPT failure. In multivariate analysis house ventilation availability and adherence to IPT

completion were significantly associated with IPT failure

Table 3: Multivariate analysis of risk factors of isoniazid preventive therapy (IPT) failure

Variable	В	P
House ventilation availability		
None	3.424	0.007*#
≥ 1 ventilation (ref)		
Adherence to IPT completion		
Incomplete	3.424	0.007*#
Complete		

^{*}p < 0.05 was considered statistically significant

[#]Logistic regression test was used

1

Discussion

Most of the subjects included in this study completed IPT for 6 months and did not develop TB. A study in South Africa about starting IPT in those who were in close contact with adult TB patients reported that only around 9% of them succeeded in completing IPT. A lack of information and education about TB disease transmission and development could be the main reason for ITP failure. Other factors for IPT failure are described by health professionals, such as uncertain INH supply, difficulties in reaching health facilities, insufficient knowledge and training for health professionals, and poor monitoring.

In this study, there were 4 subjects who developed TB disease. Therefore, the effectiveness of IPT in preventing TB disease was 95.5%. This is in line with a previous study in Indonesia that reported that none of their subject developed TB after starting IPT. A study in Rwanda¹⁰ found that IPT reached 88% effectiveness and compliance. They also stated that parents, comorbidity, overcrowded family and healthcare providers are the determinants of effectiveness and compliance in completing IPT.

Our study found that age is a significant risk factor associated with IPT failure. A study in Kenya reported that younger age (<1 year old) was not significantly associated with IPT failure⁴. BCG vaccine has been reported to induce the release of strong type-CD4 Th1 and CD8 in the first year of life. Therefore, children under 1 year old who already receive BCG vaccine rarely develop TB¹¹. Older children tend to have more interaction with adults in their daily lives and are more vulnerable to be infected both in their houses or society¹².

This study found that half the subjects who failed IPT were having malnutrition. Malnutrition is associated with IPT failure and increases the risk of IPT failure up to 14 times. It is in line with a previous study reporting that children with malnutrition are 2-5 times as likely to have TB¹³. Malnutrition is related to immunosuppression makes children vulnerable to mycobacterial invasion and disease development¹⁴ and is the most important predisposing factor for TB in areas with limited resources¹⁵.

BCG scar is significantly related to IPT failure and children who do not have the BCG scar are 7 times more likely to fail IPT. BCG vaccine has the ability to protect children from TB, especially in younger children with success rate up to 88%17,18. Moreover, a study conducted in Peru found that BCG scar was a sensitive indicator for vaccination status until the age of 3 years 19.

Our study found that a positive tuberculin test is significantly associated with IPT failure. This is in line with a previous study that reported positive tuberculin test was related to IPT failure⁴. Positive tuberculin test indicates TB infection and not TB disease and in children under 5 years old, a positive tuberculin test determines TB infection and is a risk factor for developing TB disease²⁰. Furthermore, a previous study found that tuberculin test result is an important risk factor for developing TB disease in children with TB contact²¹.

This study found that non-availability of house ventilation is associated with IPT failure. It is in accordance with a previous study in Nigeria describing that insufficient ventilation and an overcrowded family in a house would increase the risk factor of TB disease development. House ventilation itself is related to mycobacterium spread²². Inadequate house ventilation leads to bad quality of air, increases mycobacterium transmission, and increases humidity with less sunlight. Those will indeed increase the risk of TB disease development^{23,24}.

Living far from the Integrated Healthcare Centre (IHC) and infrequent IHC visits are significant risk factors of IPT failure. This is supported by a previous study in India²⁵. A study in Indonesia evaluated compliance of IPT. They reported that there were various risk factors that could reduce compliance of IPT. Difficult access and a great distance to health facilities that lead to high travel expense is often a major problem²⁶. Hence, providing health facilities that are close to their residences with easier access is mandatory. Then, information and education about IPT can be more easily accepted^{25,26}.

Adherence to IPT completion represents its compliance. Only 9.9% subjects in this study did not complete IPT. There was better compliance compared with a previous Indonesian study where 74.4% of children under five who participated in the IPT programme had low compliance²⁶. Another study in Indonesia also reported that only 49.5% of their subjects completed IPT for 6 months. Drug regimens, factors related to caregivers, support and social access were the main obstacles²⁷.

This study evaluated the side effects of IPT. We found most of subjects experienced no side effects. Around seven percent of them experienced side effects, such as loss of appetite, nausea, and tingling sensation. However, all subjects who failed IPT did not experience any side effect. Experiencing side effects of IPT was not a significant risk factor of IPT failure. This is in line with a previous study in Kenya which reported that IPT side effects were not significantly associated with IPT failure⁴.

Conclusions

Efficacy of IPT in reducing the incidence of TB disease in children below 5 years of age who were household contacts of smear positive adult TB patients was 95.5%. Low adherence to completion of therapy and unavailability of house ventilation were significantly associated with IPT failure.

References

- WHO. Global tuberculosis report 2019 [Internet]. Geneva; 2019. Available from: https://apps.who.int/iris/bitstream/handle/1 0665/329368/9789241565714eng.pdf?ua=1
- Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the pre-chemotherapy era. International Journal of Tuberculosis and Lung Disease 2004; 8(4):392–402.
- WHO. Indonesia National TB Programme: Current status of integrated community based TB service delivery and the Global Fund work plan to find missing TB cases [Internet]. 2018. Available from: https://www.who.int/tb/features_archive/i ndonesia_11apr18.pdf?ua=1
- Okwara FN, Oyore JP, Were FN, Gwer S. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study. BMC Infectious Diseases 2017; 17(1):623. https://doi.org/10.1186/s12879-017-2719-8

PMid: 28915796 PMCid: PMC5602922

- Ministry of Health of the Republic of Indonesia. Technical Guidelines for the management of TB in children 2016 1–98
- Nutrition and Metabolic Disease Working Group. Pediatric Nutrition Care. Jakarta: Indonesian Pediatric Society; 2011.
- Osman M, Hesseling AC, Beyers N, Enarson DA, Rusen ID, Lombard C, et al. Routine programmatic delivery of isoniazid preventive therapy to children in Cape Town, South Africa. Public Health Action 2013; 3(3):199–203. https://doi.org/10.5588/pha.13.0034
 PMid: 26393029 PMCid: PMC4463134

 Shivaramakrishna HR, Frederick A, Shazia A, Murali L, Satyanarayana S, Nair SA, et al. Isoniazid preventive treatment in children in two districts of South India: Does practice follow policy? *International Journal of Tuberculosis and Lung Disease* 2014; 18(8): 919–924. https://doi.org/10.5588/ijtld.14.0072 PMid: 25199005 PMCid: PMC4589200

- Triasih R, Robertson CF, Duke T, Graham SM. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. *Clinical Infectious Diseases* 2015; 60(1):12–8. https://doi.org/10.1093/cid/ciu748
 PMid: 25270649
- Birungi FM, Graham SM, Uwimana J, Musabimana A, Van Wyk B. Adherence to isoniazid preventive therapy among child contacts in Rwanda: A mixed-methods study. PLoS One 2019; 14(2):1–16. https://doi.org/10.1371/journal.pone.0211 934

PMid: 30742660 PMCid: PMC6370213

- Soares AP, Kwong Chung CKC, Choice T, Hughes EJ, Jacobs G, Van Rensburg EJ, et al. Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns. Journal of Infectious Diseases 2013; 207(7): 1084– 94. https://doi.org/10.1093/infdis/jis941 PMid: 23293360 PMCid: PMC3583271
- Seddon JA, Shingadia D. Epidemiology and disease burden of tuberculosis in children: A global perspective. *Infection* and Drug Resistance 2014; 7:153–65. https://doi.org/10.2147/IDR.S45090
 PMid: 24971023 PMCid: PMC4069045
- Cohn D, El-Sadr W. Treatment of latent tuberculosis infection. In: Reichman L, Hershfield E, editors. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker; 2000:15–30.
- Smieja M, Marchetti C, Cook D, Fm S. Isoniazid for preventing tuberculosis in non-HIV infected persons (Review). Cochrane Database Systematic Reviews 2017; 2: 1–28.

- 15. Chandrasekaran P, Saravanan Bethunaickan R, Tripathy S. Malnutrition: Modulator of immune responses in tuberculosis. Frontiers of Immunology 2017; 8: 1316. https://doi.org/10.3389/fimmu.2017.01316 PMid: 29093710 PMCid: PMC5651251
- 16. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: Efficacy and indications for vaccination and revaccination. Journal of Pediatrics (Rio J) 2006; 82(3): 45-54. https://doi.org/10.2223/JPED.1499 PMid: 16826312
- 17. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: Α meta-analysis. International Journal of Epidemiology 1993; 22(6): 1154-8. https://doi.org/10.1093/ije/22.6.1154 PMid: 8144299
- 18. Thilothammal N, Krishnamurthy PV, Runyan DK, Banu K. Does BCG vaccine prevent tuberculous meningitis? Archives of Disease in Childhood 1996; 74: 144-7. https://doi.org/10.1136/adc.74.2.144 PMid: 8660078 PMCid: PMC1511494
- 19. Santiago EM, Lawson E, Gillenwater K, Kalangi S, Lescano AG, Du Quella G, et al. A prospective study of bacillus Calmette-Guérin scar formation and tuberculin skin test reactivity in infants in Lima, Peru. Pediatrics 2003; 112(4): 298. https://doi.org/10.1542/peds.112.4.e298 PMid: 14523215
- 20. WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management [Internet]. 2018. Available from: https://apps.who.int/iris/bitstream/handle/1 0665/260233/9789241550239eng.pdf;jses sionid=59C83A51B0BE8F9EF9F1EE50E 35E4B27?sequence=1
- 21. Chan PC, Peng SSF, Chiou MY, Ling DL, Chang LY, Wang KF, et al. Risk for tuberculosis in child contacts: Development and validation of a predictive score. American Journal of Respiratory and Critical Care Medicine 2014; 189(2): 203-3.

- 22. Attah CJ, Oguche S, Egah D, Ishaya TN, Banwat M, Adgidzi AG. Risk factors associated with paediatric tuberculosis in an endemic setting. Alexandria Journal of Medicine 2018; 54(4): 403-9. https://doi.org/10.1016/j.ajme.2018.05.00
- 23. Døllner H, Ramm CT, Harstad I, Afset JE, Sagvik E. Risk of developing tuberculosis after brief exposure in Norwegian children: Results of a contact investigation. BMJ Open 2012; 2: e001816. https://doi.org/10.1136/bmjopen-2012-001816 PMid: 23135543 PMCid: PMC3533020
- 24. Gupta D, Das K, Balamughesh T, Aggarwal AN, Jindal SK. Role of socioeconomic factors in tuberculosis prevalence. Indian Journal of Tuberculosis 2004; 51: 27-31.
- 25. Singh AR, Kharate A, Bhat P, Kokane AM, Bali S, Sahu S, et al. Isoniazid preventive therapy among children living with tuberculosis patients: Is it working? A mixed-method study from Bhopal, India. Indian Journal of Tropical Pediatrics 2017; 63: 274-85. https://doi.org/10.1093/tropej/fmw086 PMid: 28082666 PMCid: PMC5914486
- 26. Rutherford M, Hill P, Ruslami R, Maharani W, Alisjahbana B, Yulita I, et al. Adherence to isoniazid npreventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Research Notes 2012; 5: 1-7. https://doi.org/10.1186/1756-0500-5-7 PMid: 22221424 PMCid: PMC3287144
- 27. Triasih R, Padmawati RS, Duke T, Robertson C, Sawyer SM, Graham SM. A mixed-methods evaluation of adherence to preventive treatment among child tuberculosis contacts in Indonesia. International Journal of Tuberculosis and Lung Disease 2016; 20(8): 1078-83. https://doi.org/10.5588/ijtld.15.0952 PMid: 27393543

tuberculosis **ORIGINALITY REPORT** 17% 13% INTERNET SOURCES **PUBLICATIONS** STUDENT PAPERS SIMILARITY INDEX **PRIMARY SOURCES** K S Poornima, P Parthasarathi Reddy, M **7**% Shakeel Anjum, M Monica, K Yadav Rao, Irram Abbas. "Parental perceptions towards passive smoking: a cross-sectional survey in Vikarabad town, India", Sri Lanka Journal of Child Health, 2016 **Publication** "Prevention in developing countries", The 1 % Lancet, 1995 **Publication** bmcinfectdis.biomedcentral.com Internet Source scholar.archive.org Internet Source "Handbook of Tuberculosis", Springer Science 5 and Business Media LLC, 2017 Publication

Bmcinfectdis.biomedcentral.com
Internet Source

		<1%
16	impactfactor.org Internet Source	<1 %
17	repository.kemu.ac.ke:8080 Internet Source	<1%
18	WWW.gov.za Internet Source	<1%
19	Anuradha Bose. "Intermittent versus daily therapy for treating tuberculosis in children", Cochrane Database of Systematic Reviews Protocols, 07/08/2009 Publication	<1%
20	E. M. Santiago, E. Lawson, K. Gillenwater, S. Kalangi et al. "A Prospective Study of Bacillus Calmette-Guerin Scar Formation and Tuberculin Skin Test Reactivity in Infants in Lima, Peru", PEDIATRICS, 2003 Publication	<1%
21	Grace A. Shayo, Candida Moshiro, Said Aboud, Muhammad Bakari, Ferdinand M. Mugusi. "Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania", BMC Infectious Diseases, 2015	<1%

22	Jonas Hector, Suzanne T. Anderson, Gertrude Banda, Mercy Kamdolozi et al. "TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi", BMC Infectious Diseases, 2017 Publication	<1%
23	Wwwnc.cdc.gov Internet Source	<1%
24	edoc.ub.uni-muenchen.de Internet Source	<1%
25	jfrh.tums.ac.ir Internet Source	<1%
26	pubs.sciepub.com Internet Source	<1%
27	www.jstage.jst.go.jp Internet Source	<1%
28	M Chello. "Simvastatin attenuates leucocyte- endothelial interactions after coronary revascularisation with cardiopulmonary bypass", Heart, 2003 Publication	<1%
29	Masanja Robert, Jim Todd, Bernard J Ngowi, Sia Msuya et al. "Determinants of Isoniazid Preventive Therapy Completion among People Living with HIV Attended Care and Treatment Clinics from 2013 to 2017 in Dar	<1%

es Salaam Region, Tanzania. A cross-sectional analytical study", Research Square Platform LLC, 2019

Publication

Ming-Chao Tsai, Yi-Hao Yen, Kuo-Chin Chang, Chao-Hung Hung, Chien-Hung Chen, Ming-Tsung Lin, Tsung-Hui Hu. "Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection", Research Square Platform LLC, 2019

<1%

Publication

Rachel Dwilow, Charles Hui, Fatima Kakkar, Ian Kitai. "Chapter 9: Pediatric tuberculosis", Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022

<1%

Publication

Shishi Xing, Yuhe Wang, Xue He, Wei Yang, Qunying Hu, Yongjun He, Dongya Yuan, Tianbo Jin. "CYP2C8 and CYP2E1 genetic variants increase risk of tuberculosis in northwest Chinese Han population", Infection, Genetics and Evolution, 2021

<1%

Publication

Susan S van Wyk, Anthony J Reid, Anna M Mandalakas, Donald A Enarson, Nulda Beyers, Julie Morrison, Anneke C Hesseling. "Operational challenges in managing Isoniazid

<1%

Preventive Therapy in child contacts: A highburden setting perspective", BMC Public Health, 2011

Publication

Publication

Publication

Off

Punam Mangtani, Patrick Nguipdop-Djomo, Ruth H Keogh, Lucy Trinder et al. "Observational study to estimate the changes in the effectiveness of bacillus Calmette– Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK", Health Technology Assessment, 2017

<1%

35

Sukmal Fahri, Benediktus Yohan, Hidayat Trimarsanto, S. Sayono et al. "Molecular Surveillance of Dengue in Semarang, Indonesia Revealed the Circulation of an Old Genotype of Dengue Virus Serotype-1", PLoS Neglected Tropical Diseases, 2013

<1%

Exclude quotes

Exclude bibliography

Exclude matches

Off

GRADEMARK REPORT		
FINAL GRADE	GENERAL COMMENTS	
/0	Instructor	
PAGE 1		
PAGE 2		
PAGE 3		
PAGE 4		
PAGE 5		
PAGE 6		